Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
Matt Kaeberlein, a longevity researcher and CEO of Optispan, had symptoms of low testosterone. He got his levels tested in his 50s and gradually began testosterone replacement therapy (TRT). He said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results